New agents for the treatment of renal osteodystrophy.
Ledger
Séadna
S
London Health Sciences Centre, London, Ontario. Seadna.Ledger@lhsc.on.ca
D001812:Blood-Brain Barrier / Q000187:drug effects; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000069449:Cinacalcet; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D007811:Lanthanum / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D008657:Metabolic Clearance Rate; D009281:Naphthalenes / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D018579:Patient Selection; D006435:Renal Dialysis; D016896:Treatment Outcome
D009281:Naphthalenes; C119467:lanthanum carbonate; D007811:Lanthanum; D000069449:Cinacalcet